Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 08:07 ET | Quelle: Curanex Pharmaceuticals Inc

Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development Company

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)...
30. März 2026 17:35 ET | Quelle: Curanex Pharmaceuticals Inc

Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) --...
18. März 2026 08:00 ET | Quelle: Curanex Pharmaceuticals Inc

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March ...